Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (8072)	12/16/1998 7:51:00 AM
From: Robert K.	Read Replies (4) \| Respond to of 17367

RobertS>your comment>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> >>>"I agree that your presented scenario may very well unfold just as you envision. The problem with many of the posts on this board is that just because BPI is apparently "safe", some believe this entitles the utilization of BPI for any indication where it may prove to be of benefit. After all, if its "safe" why not use it? Such utopian views do not account for real world circumstances (such as financial aspects) and lead to hyped potential market size, IMO, for BPI." end(RobertS) >>>>>>>>>>>Start RobertK> I Agree that bpi may not be used in situations where less expensive therapies may work ( or may even work better). My questions I put back to you are these>>> What other anti-endotoxins are available? What other cascade stoppers are available? What other antibiotic potentiators are available? Is antibiotic resistance a problem that is easily and cheaply met? If bpi does reduce serious complications will it be used? The REAL question is>>>Whats the most cost effective product(that works)? And one MUST (IMO) focus on the word>WORKS. Try to answer as many questions as you can (avoiding the least)